{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:30:32Z","timestamp":1784730632877,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Dutch Ministry of Public Health, Welfare, and Sports"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immun Ageing"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune responses to vaccination vary widely between individuals. The aim of this study was to identify health-related variables potentially underlying the antibody responses to SARS-CoV-2 vaccination in older persons. We recruited participants in the long-running Doetinchem Cohort Study (DCS) who underwent vaccination as part of the national COVID-19 program, and measured antibody concentrations to SARS-CoV-2 Spike protein (S1) and Nucleoprotein (N) at baseline (T0), and a month after both the first vaccination (T1), and the second vaccination (T2). Associations between the antibody concentrations and demographic variables, including age, sex, socio-economic status (SES), comorbidities (cardiovascular diseases and immune mediated diseases), various health parameters (cardiometabolic markers, inflammation markers, kidney- and lung function) and a composite measure of frailty (\u2018frailty index\u2019, ranging from 0 to 1) were tested using multivariate models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 1457 persons aged 50 to 92 years old. Of these persons 1257 were infection na\u00efve after their primary vaccination series. The majority (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009954) of these individuals were vaccinated with two doses of BNT162b2 (Pfizer) and their data were used for further analysis. A higher frailty index was associated with lower anti-S1 antibody responses at T1 and T2 for both men (\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>T1<\/jats:sub>\n                      \u2009=\u2009-0.095,\n                      <jats:italic>P<\/jats:italic>\n                      <jats:sub>T1<\/jats:sub>\n                      \u2009=\u20090.05;\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>T2<\/jats:sub>\n                      \u2009=\u2009-0.11,\n                      <jats:italic>P<\/jats:italic>\n                      <jats:sub>T2<\/jats:sub>\n                      \u2009=\u20090.02) and women (\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>T1<\/jats:sub>\n                      \u2009=\u2009-0.24,\n                      <jats:italic>P<\/jats:italic>\n                      <jats:sub>T1<\/jats:sub>\n                      \u2009&lt;\u20090.01;\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sub>T2<\/jats:sub>\n                      \u2009=\u2009-0.15,\n                      <jats:italic>P<\/jats:italic>\n                      <jats:sub>T2<\/jats:sub>\n                      \u2009&lt;\u20090.01). After correcting for age and sex the frailty index was also associated with the relative increase in anti-S1 IgG concentrations between the two vaccinations (\u03b2\u2009=\u20091.6,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01). Within the construct of frailty, history of a cardiac catheterization, diabetes, gastrointestinal disease, a cognitive speed in the lowest decile of the population distribution, and impaired lung function were associated with lower antibody responses after both vaccinations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Components of frailty play a key role in the primary vaccination response to the BNT162b2 vaccine within an ageing population. Older persons with various comorbidities have a lowered immune response after their first vaccination, and while frail and sick older persons see a stronger increase after their second vaccination compared to healthy people, they still have a lower antibody response after their second vaccination.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12979-023-00382-4","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T03:02:27Z","timestamp":1698202947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Potential determinants of antibody responses after vaccination against SARS-CoV-2 in older persons: the Doetinchem Cohort Study"],"prefix":"10.1186","volume":"20","author":[{"given":"Yunus","family":"Kuijpers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Susan J.","family":"Picavet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"de Rond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-l\u00e8ne","family":"de Zeeuw-Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryanne","family":"Rutkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Gijsbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Slits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Engelfriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Buisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. M. Monique","family":"Verschuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"issue":"2","key":"382_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","volume":"28","author":"T Fiolet","year":"2022","unstructured":"Fiolet T, Kherabi Y, MacDonald C-J, Ghosn J, Peiffer-Smadja N. Comparing covid-19 vaccines for their characteristics, efficacy and effectiveness against SARS-COV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202\u201321.","journal-title":"Clin Microbiol Infect"},{"key":"382_CR2","doi-asserted-by":"publisher","first-page":"101205","DOI":"10.1016\/j.arr.2020.101205","volume":"65","author":"Y Chen","year":"2021","unstructured":"Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. 2021;65:101205.","journal-title":"Ageing Res Rev"},{"issue":"12","key":"382_CR3","doi-asserted-by":"publisher","first-page":"e006434","DOI":"10.1136\/bmjgh-2021-006434","volume":"6","author":"K Romero Starke","year":"2021","unstructured":"Romero Starke K, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health. 2021;6(12):e006434.","journal-title":"BMJ Glob Health"},{"key":"382_CR4","doi-asserted-by":"publisher","first-page":"513557","DOI":"10.3389\/fpubh.2021.513557","volume":"9","author":"E Jaul","year":"2021","unstructured":"Jaul E, Barron J. Characterizing the heterogeneity of aging: a vision for a staging system for aging. Front Public Health. 2021;9:513557.","journal-title":"Front Public Health"},{"issue":"36","key":"382_CR5","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1016\/j.vaccine.2017.07.062","volume":"36","author":"GA Poland","year":"2018","unstructured":"Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: a review. Vaccine. 2018;36(36):5350\u20137.","journal-title":"Vaccine"},{"issue":"7872","key":"382_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","volume":"596","author":"DA Collier","year":"2021","unstructured":"Collier DA, Ferreira IA, Kotagiri P, Datir RP, Lim EY, Touizer E, et al. Age-related immune response heterogeneity to SARS-COV-2 vaccine BNT162b2. Nature. 2021;596(7872):417\u201322.","journal-title":"Nature"},{"key":"382_CR7","doi-asserted-by":"publisher","first-page":"942796","DOI":"10.3389\/fimmu.2022.942796","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Dong C, Han Y, Gu Z, Sun C. Immunosenescence, aging and successful aging. Front Immunol. 2022;13:942796.","journal-title":"Front Immunol"},{"issue":"9","key":"382_CR8","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3390\/vaccines10091480","volume":"10","author":"LL van den Hoogen","year":"2022","unstructured":"van den Hoogen LL, Boer M, Postema A, de Rond L, de Zeeuw-Brouwer ML, Pronk I, et al. Reduced antibody acquisition with increasing age following vaccination with BNT162b2: results from two longitudinal cohort studies in the Netherlands. Vaccines. 2022;10(9):1480.","journal-title":"Vaccines"},{"key":"382_CR9","doi-asserted-by":"publisher","first-page":"101455","DOI":"10.1016\/j.arr.2021.101455","volume":"71","author":"N Veronese","year":"2021","unstructured":"Veronese N, Petrovic M, Benetos A, Denkinger M, Gudmundsson A, Knol W, et al. Underrepresentation of older adults in clinical trials on COVID-19 vaccines: a systematic review. Ageing Res Rev. 2021;71:101455.","journal-title":"Ageing Res Rev"},{"issue":"10","key":"382_CR10","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2022.3227","volume":"8","author":"S Haggenburg","year":"2022","unstructured":"Haggenburg S, Hofsink Q, Lissenberg-Witte BI, Broers AE, van Doesum JA, van Binnendijk RS, et al. Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for covid-19. JAMA Oncol. 2022;8(10):1477. https:\/\/doi.org\/10.1001\/jamaoncol.2022.3227.","journal-title":"JAMA Oncol"},{"issue":"11","key":"382_CR11","doi-asserted-by":"publisher","first-page":"e778","DOI":"10.1016\/s2665-9913(21)00222-8","volume":"3","author":"L Boekel","year":"2021","unstructured":"Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZL, Kummer LY, et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol. 2021;3(11):e778-88. https:\/\/doi.org\/10.1016\/s2665-9913(21)00222-8.","journal-title":"Lancet Rheumatol"},{"key":"382_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ejca.2021.10.013","volume":"159","author":"S Tran","year":"2021","unstructured":"Tran S, Truong TH, Narendran A. Evaluation of COVID-19 vaccine response in patients with cancer: an interim analysis. Eur J Cancer. 2021;159:259\u201374.","journal-title":"Eur J Cancer"},{"issue":"12","key":"382_CR13","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41581-021-00491-7","volume":"17","author":"S Caillard","year":"2021","unstructured":"Caillard S, Thaunat O. Covid-19 vaccination in kidney transplant recipients. Nat Rev Nephrol. 2021;17(12):785\u20137.","journal-title":"Nat Rev Nephrol"},{"issue":"8","key":"382_CR14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41591-021-01435-1","volume":"27","author":"P Loubet","year":"2021","unstructured":"Loubet P, Wittkop L, Tartour E, Parfait B, Barrou B, Blay J-Y, et al. A French cohort for assessing COVID-19 vaccine responses in specific populations. Nat Med. 2021;27(8):1319\u201321.","journal-title":"Nat Med"},{"issue":"2","key":"382_CR15","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3390\/vaccines10020260","volume":"10","author":"W Witkowski","year":"2022","unstructured":"Witkowski W, Gerlo S, De Smet E, Wejda M, Acar D, Callens S, Heytens S, Padalko E, Vercruysse H, Cools P, Vandekerckhove L. Humoral and cellular responses to COVID-19 vaccination indicate the need for post-vaccination testing in frail population. Vaccines (Basel). 2022;10(2):260. https:\/\/doi.org\/10.3390\/vaccines10020260.","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"382_CR16","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1016\/S2666-7568(22)00012-5","volume":"3","author":"DC Vinh","year":"2022","unstructured":"Vinh DC, Gouin J-P, Cruz-Santiago D, Canac-Marquis M, Bernier S, Bobeuf F, et al. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (uncover): an interim report from a prospective observational cohort study. Lancet Healthy Longev. 2022;3(3):e166\u201375.","journal-title":"Lancet Healthy Longev"},{"issue":"7","key":"382_CR17","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1093\/gerona\/glac095","volume":"77","author":"CT Semelka","year":"2022","unstructured":"Semelka CT, DeWitt ME, Callahan KE, Herrington DM, Alexander-Miller MA, Yukich JO, et al. Frailty and COVID-19 mrna vaccine antibody response in the COVID-19 Community Research Partnership. J Gerontol A. 2022;77(7):1366\u201370.","journal-title":"J Gerontol A"},{"issue":"6","key":"382_CR18","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/ije\/dym292","volume":"37","author":"W Verschuren","year":"2008","unstructured":"Verschuren W, Blokstra A, Picavet H, Smit H. Cohort profile: the Doetinchem cohort study. Int J Epidemiol. 2008;37(6):1236\u201341.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"382_CR19","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1093\/ije\/dyx103","volume":"46","author":"HS Picavet","year":"2017","unstructured":"Picavet HS, Blokstra A, Spijkerman AM, Verschuren WM. Cohort profile update: the Doetinchem Cohort Study 1987\u20132017: lifestyle, health and chronic diseases in a life course and ageing perspective. Int J Epidemiol. 2017;46(6):1751\u20131751g. https:\/\/doi.org\/10.1093\/ije\/dyx103.","journal-title":"Int J Epidemiol"},{"issue":"9","key":"382_CR20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/s2213-2600(21)00220-4","volume":"9","author":"Y Lustig","year":"2021","unstructured":"Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, et al. BNT162B2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med. 2021;9(9):999\u20131009. https:\/\/doi.org\/10.1016\/s2213-2600(21)00220-4.","journal-title":"Lancet Respir Med"},{"key":"382_CR21","doi-asserted-by":"publisher","first-page":"940357","DOI":"10.3389\/fimmu.2022.940357","volume":"13","author":"AB Boroumand","year":"2022","unstructured":"Boroumand AB, Forouhi M, Karimi F, Moghadam AS, Naeini LG, Kokabian P, et al. Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: a systematic review. Front Immunol. 2022;13:940357. https:\/\/doi.org\/10.3389\/fimmu.2022.940357.","journal-title":"Front Immunol"},{"key":"382_CR22","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41587-020-00796-1","volume":"39","author":"S Trump","year":"2021","unstructured":"Trump S, Lukassen S, Anker MS, et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nat Biotechnol. 2021;39:705\u201316. https:\/\/doi.org\/10.1038\/s41587-020-00796-1.","journal-title":"Nat Biotechnol"},{"key":"382_CR23","doi-asserted-by":"publisher","first-page":"9028969","DOI":"10.1155\/2022\/9028969","volume":"2022","author":"D Oosthuizen","year":"2022","unstructured":"Oosthuizen D, Sturrock ED. Exploring the impact of ACE inhibition in immunity and disease. J Renin Angiotensin Aldosterone Syst. 2022;2022:9028969. https:\/\/doi.org\/10.1155\/2022\/9028969.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"9","key":"382_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41577-019-0177-9","volume":"19","author":"NA Duggal","year":"2019","unstructured":"Duggal NA, Niemiro G, Harridge SD, Simpson RJ, Lord JM. Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity? Nat Rev Immunol. 2019;19(9):563\u201372. https:\/\/doi.org\/10.1038\/s41577-019-0177-9.","journal-title":"Nat Rev Immunol"},{"key":"382_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.bbi.2021.05.016","volume":"96","author":"GD Batty","year":"2021","unstructured":"Batty GD, Deary IJ, Fawns-Ritchie C, Gale CR, Altschul D. Pre-pandemic cognitive function and covid-19 vaccine hesitancy: cohort study. Brain Behav Immun. 2021;96:100\u20135. https:\/\/doi.org\/10.1016\/j.bbi.2021.05.016.","journal-title":"Brain Behav Immun"},{"issue":"9","key":"382_CR26","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/infdis\/jiaa479","volume":"222","author":"G den Hartog","year":"2020","unstructured":"den Hartog G, Schepp RM, Kuijer M, GeurtsvanKessel C, van Beek J, Rots N, et al. SARS-COV-2\u2013specific antibody detection for seroepidemiology: a multiplex analysis approach accounting for accurate seroprevalence. J Infect Dis. 2020;222(9):1452\u201361. https:\/\/doi.org\/10.1093\/infdis\/jiaa479.","journal-title":"J Infect Dis"},{"key":"382_CR27","unstructured":"World Health Organization (WHO). First who international standard for anti-SARS-cov-2 immunoglobulin (human) 2020. Available from: https:\/\/www.nibsc.org\/documents\/ifu\/20-136.pdf. Cited 2023 Jul 11."},{"issue":"12","key":"382_CR28","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/cid\/ciab264","volume":"73","author":"ER Vos","year":"2021","unstructured":"Vos ER, van Boven M, den Hartog G, Backer JA, Klinkenberg D, van Hagen CC, et al. Associations between measures of social distancing and severe acute respiratory syndrome coronavirus 2 seropositivity: a nationwide population-based study in the Netherlands. Clin Infect Dis. 2021;73(12):2318\u201321. https:\/\/doi.org\/10.1093\/cid\/ciab264.","journal-title":"Clin Infect Dis"},{"issue":"15","key":"382_CR29","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.vaccine.2022.03.009","volume":"40","author":"LL van den Hoogen","year":"2022","unstructured":"van den Hoogen LL, Smits G, van Hagen CCE, Wong D, Vos ERA, van Boven M, et al. Seropositivity to nucleoprotein to detect mild and asymptomatic SARS-COV-2 infections: a complementary tool to detect breakthrough infections after covid-19 vaccination? Vaccine. 2022;40(15):2251\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.009.","journal-title":"Vaccine"},{"key":"382_CR30","doi-asserted-by":"publisher","first-page":"110674","DOI":"10.1016\/j.exger.2019.110674","volume":"125","author":"LD Samson","year":"2019","unstructured":"Samson LD, Boots AM, Verschuren WMM, Picavet HS, Engelfriet P, Buisman A-M. Frailty is associated with elevated CRP trajectories and higher numbers of neutrophils and monocytes. Exp Gerontol. 2019;125:110674. https:\/\/doi.org\/10.1016\/j.exger.2019.110674.","journal-title":"Exp Gerontol"},{"issue":"2","key":"382_CR31","doi-asserted-by":"publisher","first-page":"e1374","DOI":"10.1002\/cti2.1374","volume":"11","author":"LD Samson","year":"2022","unstructured":"Samson LD, Buisman A, Ferreira JA, Picavet HS, Verschuren WM, Boots AM, et al. Inflammatory marker trajectories associated with frailty and ageing in a 20-year longitudinal study. Clin Transl Immunol. 2022;11(2):e1374. https:\/\/doi.org\/10.1002\/cti2.1374.","journal-title":"Clin Transl Immunol"}],"container-title":["Immunity &amp; Ageing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12979-023-00382-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12979-023-00382-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12979-023-00382-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T21:28:21Z","timestamp":1700256501000},"score":1,"resource":{"primary":{"URL":"https:\/\/immunityageing.biomedcentral.com\/articles\/10.1186\/s12979-023-00382-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["382"],"URL":"https:\/\/doi.org\/10.1186\/s12979-023-00382-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3275160\/v1","asserted-by":"object"}]},"ISSN":["1742-4933"],"issn-type":[{"value":"1742-4933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,25]]},"assertion":[{"value":"18 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained through The Medical Research Ethics Committee Utrecht for finger prick blood sampling in the majority of the DCS participants (NL76551.041.21, EudraCT 2021-001976-40) and for finger prick blood sampling as well as venapunction in a small part of the participants (NL74843.041.20, EudraCT 2020-003620-16 and NL76719.041.21, EudraCT 2021-002363-22). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}